Matthias Tschöp

Matthias Tschöp is the CEO of Helmholtz Munich, Vice President of the German Helmholtz Association and Alexander-von-Humboldt Professor at the Technical University of Munich. Tschöp unraveled fundamental gut-brain signals to discover the first highly effective drugs for human obesity in collaboration with the chemist Richard DiMarchi - the dual and triple gut hormone multi-agonists. A first representative is FDA-approved, others are successfully progressing through clinical trials. Tschöp has received numerous honors and awards, including the Banting Medal (2023), the Heinrich Wieland Prize (2023), the Schering Prize (2023), the EASD-Lilly Centennial Prize (2022) and the Ernst Jung Prize (2021). He holds an adjunct professorship at Yale University and an honorary doctorate at Leipzig University. He was elected a member of the German, Bavarian, and European Academies of Sciences, the American Society for Clinical Investigation and the Association of American Physicians.